SCHEMBL13340280

SCHEMBL13340280

C[C@H](Nc1cncc(-c2cccc(N3CCOCC3)c2)n1)c1cccc(NC(=O)c2cccc(C(F)(F)F)c2)c1

nearest known ligand 0.63

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 4/20 0.63
BRAF P15056 16/20 0.57
RAF1 P04049 15/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13340266 0.90 CSF1R (0.61) CSF1RBRAFRAF1
SCHEMBL19447192 0.90 CSF1R (0.61) CSF1RBRAFRAF1
SCHEMBL13340395 0.89 CSF1R (0.62) CSF1RBRAFRAF1
SCHEMBL13340424 0.88 CSF1R (0.57) CSF1RBRAF
SCHEMBL13340431 0.88 CSF1R (0.61) CSF1RBRAFRAF1
SCHEMBL13340272 0.87 CSF1R (0.65) CSF1RBRAFRAF1
SCHEMBL13340410 0.86 CSF1R (0.65) CSF1RBRAFRAF1
SCHEMBL19447228 0.86 CSF1R (0.65) CSF1RBRAFRAF1
SCHEMBL3475477 0.86 CSF1R (0.64) CSF1RBRAFRAF1
SCHEMBL3475478 0.86 CSF1R (0.64) CSF1RBRAFRAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2848610-B1 Inhibitors of kinase activity YM BIOSCIENCES AUSTRALIA PTY (AU) 2017-10-11 EP disclosed
EP-3048099-A2 INHIBITORS OF KINASE ACTIVITY YM BioSciences Australia Pty Ltd (AU) 2016-07-27 EP disclosed
US-9029386-B2 Pyridine derivatives useful as kinase inhibitors GILEAD SCIENCES, INC. (US) 2015-05-12 US disclosed
EP-2848610-A1 Inhibitors of kinase activity YM BioSciences Australia Pty Ltd (AU) 2015-03-18 EP disclosed
US-8461161-B2 Substituted pyrazines as inhibitors of kinase activity YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2013-06-11 US disclosed
US-8461161-B2 Substituted pyrazines as inhibitors of kinase activity YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2013-06-11 US disclosed
US-20130137660-A1 INHIBITORS OF KINASE ACTIVITY YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2013-05-30 US disclosed
US-20100130447-A1 INHIBITORS OF KINASE ACTIVITY YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2010-05-27 US disclosed
US-20100130447-A1 INHIBITORS OF KINASE ACTIVITY YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137660-A1 INHIBITORS OF KINASE ACTIVITY FRK, LCK, FLT3 CSF1R 62/4885BRAF 375/4885RAF1 347/4885
US-20100130447-A1 INHIBITORS OF KINASE ACTIVITY FRK, LCK, FLT3 CSF1R 62/4885BRAF 375/4885RAF1 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.